Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PFE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PFE and 80,000+ other tickers.
See exactly how PFE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PFE and 80,000+ other tickers.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables…
Pfizer's 5.91% dividend yield anchors the story, and a pipeline finally catching a bid adds meaningful upside. My 24/7 Wall St. price target reflects that.
Pfizer's stock is down big due to concerns about its future. The company's acquisitions have been paying off and have been boosting its top line.
AbbVie has successfully pivoted to new immunology leaders to offset the loss of exclusivity for its top-selling drug. Pfizer is utilizing its robust cash position to acquire oncology assets and replenish its product pipeline.
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.
Investors won't start seeing the fruits of Pfizer's current efforts for several more years. A handful of its top-selling drugs will be losing their patent protection in the meantime.